Literature DB >> 26286643

Variants in RBP4 and AR genes modulate age at onset in familial amyloid polyneuropathy (FAP ATTRV30M).

Diana Santos1,2, Teresa Coelho3, Miguel Alves-Ferreira1,2, Jorge Sequeiros1,2, Denisa Mendonça2,4, Isabel Alonso1,2, Carolina Lemos1,2, Alda Sousa1,2.   

Abstract

Familial amyloid polyneuropathy (FAP) ATTRV30M is a neurodegenerative disorder due to point mutations in the transthyretin gene, with V30M being the commonest. FAP ATTRV30M shows a wide variation in age at onset (AO) between clusters, families and generations. Portuguese patients also show remarkable AO differences between genders. Genes found to be associated with FAP ATTRV30M pathways may act as AO modifiers. Our aim was to further explore the role of APCS and RBP4 genes and to study for the first time the involvement of sex-linked genetic modifiers - AR and HSD17B1 genes - in AO variation in Portuguese families. We collected DNA from a sample of 318 patients, currently under follow-up. A total of 18 tagging SNPs from APCS, RBP4, AR and HSD17B1 and 5 additional SNPs from APCS and RBP4 previously studied were genotyped. To account for nonindependency of AO between members of the same family, we used generalized estimating equations (GEEs). We found that APCS and RBP4 were associated with late AO. In addition, rs11187545 of the RBP4 was associated with an early AO. For the AR, in the male group three SNPs were associated with an early AO, whereas in the female group four were associated with both an early and later AO. These results strengthened the role of APCS and RBP4 genes and revealed for the first time the contribution of AR genes as an AO modifier in both males and females. These findings may have important implications in genetic counseling and for new therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26286643      PMCID: PMC4930087          DOI: 10.1038/ejhg.2015.180

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  36 in total

Review 1.  Computational analysis of gene-gene interactions using multifactor dimensionality reduction.

Authors:  Jason H Moore
Journal:  Expert Rev Mol Diagn       Date:  2004-11       Impact factor: 5.225

Review 2.  Estrogen and testosterone therapies in multiple sclerosis.

Authors:  Stefan M Gold; Rhonda R Voskuhl
Journal:  Prog Brain Res       Date:  2009       Impact factor: 2.453

3.  Longitudinal data analysis for discrete and continuous outcomes.

Authors:  S L Zeger; K Y Liang
Journal:  Biometrics       Date:  1986-03       Impact factor: 2.571

4.  Biochemical but not clinical vitamin A deficiency results from mutations in the gene for retinol binding protein.

Authors:  H K Biesalski; J Frank; S C Beck; F Heinrich; B Illek; R Reifen; H Gollnick; M W Seeliger; B Wissinger; E Zrenner
Journal:  Am J Clin Nutr       Date:  1999-05       Impact factor: 7.045

5.  Complement C1Q polymorphisms modulate onset in familial amyloidotic polyneuropathy TTR Val30Met.

Authors:  Efthimios Dardiotis; Pantelitsa Koutsou; Eleni Zamba-Papanicolaou; Ilia Vonta; Marilena Hadjivassiliou; Georgios Hadjigeorgiou; Marios Cariolou; Kyproula Christodoulou; Theodoros Kyriakides
Journal:  J Neurol Sci       Date:  2009-06-03       Impact factor: 3.181

6.  17beta-estradiol induces transthyretin expression in murine choroid plexus via an oestrogen receptor dependent pathway.

Authors:  T Quintela; I Gonçalves; G Baltazar; C H Alves; M J Saraiva; C R A Santos
Journal:  Cell Mol Neurobiol       Date:  2009-01-07       Impact factor: 5.046

7.  5Alpha-dihydrotestosterone up-regulates transthyretin levels in mice and rat choroid plexus via an androgen receptor independent pathway.

Authors:  T Quintela; C H Alves; I Gonçalves; G Baltazar; M J Saraiva; C R A Santos
Journal:  Brain Res       Date:  2008-07-02       Impact factor: 3.252

8.  The neural androgen receptor: a therapeutic target for myelin repair in chronic demyelination.

Authors:  Rashad Hussain; Abdel M Ghoumari; Bartosz Bielecki; Jérôme Steibel; Nelly Boehm; Philippe Liere; Wendy B Macklin; Narender Kumar; René Habert; Sakina Mhaouty-Kodja; François Tronche; Regine Sitruk-Ware; Michael Schumacher; M Said Ghandour
Journal:  Brain       Date:  2013-01       Impact factor: 13.501

9.  Cell- and gene-specific regulation of primary target genes by the androgen receptor.

Authors:  Eric C Bolton; Alex Y So; Christina Chaivorapol; Christopher M Haqq; Hao Li; Keith R Yamamoto
Journal:  Genes Dev       Date:  2007-08-15       Impact factor: 11.361

10.  Inhibition of TTR aggregation-induced cell death--a new role for serum amyloid P component.

Authors:  Karin Andersson; Malgorzata Pokrzywa; Ingrid Dacklin; Erik Lundgren
Journal:  PLoS One       Date:  2013-02-04       Impact factor: 3.240

View more
  16 in total

1.  Non-coding variants contribute to the clinical heterogeneity of TTR amyloidosis.

Authors:  Andrea Iorio; Antonella De Lillo; Flavio De Angelis; Marco Di Girolamo; Marco Luigetti; Mario Sabatelli; Luca Pradotto; Alessandro Mauro; Anna Mazzeo; Claudia Stancanelli; Federico Perfetto; Sabrina Frusconi; Filomena My; Dario Manfellotto; Maria Fuciarelli; Renato Polimanti
Journal:  Eur J Hum Genet       Date:  2017-06-21       Impact factor: 4.246

2.  Phenotypic variability of TTR Val122Ile mutation: a Caucasian patient with axonal neuropathy and normal heart.

Authors:  Claudia Stancanelli; Luca Gentile; Gianluca Di Bella; Fabio Minutoli; Massimo Russo; Giuseppe Vita; Anna Mazzeo
Journal:  Neurol Sci       Date:  2016-11-12       Impact factor: 3.307

Review 3.  Role of carotenoids and retinoids during heart development.

Authors:  Ioan Ovidiu Sirbu; Aimée Rodica Chiş; Alexander Radu Moise
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2020-01-22       Impact factor: 4.698

Review 4.  Update on Disease-Specific Biomarkers in Transthyretin Cardiac Amyloidosis.

Authors:  Caleb J Hood; Nicholas S Hendren; Rose Pedretti; Lori R Roth; Lorena Saelices; Justin L Grodin
Journal:  Curr Heart Fail Rep       Date:  2022-08-05

Review 5.  Current and Emerging Therapies for Hereditary Transthyretin Amyloidosis: Strides Towards a Brighter Future.

Authors:  Laura Obici; Roberta Mussinelli
Journal:  Neurotherapeutics       Date:  2021-11-30       Impact factor: 6.088

Review 6.  Transthyretin familial amyloid polyneuropathy: an update.

Authors:  Violaine Plante-Bordeneuve
Journal:  J Neurol       Date:  2017-12-16       Impact factor: 4.849

7.  Life paths of patients with transthyretin-related familial amyloid polyneuropathy Val30Met: a descriptive study.

Authors:  Alice Lopes; Alexandra Sousa; Isabel Fonseca; Margarida Branco; Carla Rodrigues; Teresa Coelho; Jorge Sequeiros; Paula Freitas
Journal:  J Community Genet       Date:  2017-10-19

8.  Phenome-wide association study of TTR and RBP4 genes in 361,194 individuals reveals novel insights in the genetics of hereditary and wildtype transthyretin amyloidoses.

Authors:  Antonella De Lillo; Flavio De Angelis; Marco Di Girolamo; Marco Luigetti; Sabrina Frusconi; Dario Manfellotto; Maria Fuciarelli; Renato Polimanti
Journal:  Hum Genet       Date:  2019-10-29       Impact factor: 4.132

9.  Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy.

Authors:  Hartmut H-J Schmidt; Fabio Barroso; Alejandra González-Duarte; Isabel Conceição; Laura Obici; Denis Keohane; Leslie Amass
Journal:  Muscle Nerve       Date:  2016-09       Impact factor: 3.217

10.  Familial amyloid polyneuropathy in Portugal: New genes modulating age-at-onset.

Authors:  Diana Santos; Teresa Coelho; Miguel Alves-Ferreira; Jorge Sequeiros; Denisa Mendonça; Isabel Alonso; Carolina Lemos; Alda Sousa
Journal:  Ann Clin Transl Neurol       Date:  2016-12-20       Impact factor: 4.511

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.